Last Updated on March 22, 2022 by GlobeNewsWire
ZURICH, Switzerland, March 22, 2022 (GLOBE NEWSWIRE) — CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics based on its proprietary antibody-based T cell engager technology (M-gager(R)), today announced that preclinical data for the Company’s lead development candidate, CDR404, a first-in-class dual MAGE-A4 T-cell engager, has been selected for a poster presentation at the upcoming 2022 American Association for Cancer Research Annual Meeting, being held April 8-13 in New Orleans, LA.
Details for the poster presentation are as follows:
Abstract Number: #1818
Poster Title: Enhanced Anti-tumor Responses with a Novel Dual pMHC T-cell Engager Bispecific Antibody
Session Number & Name: Therapeutic Antibodies 2
Session Date: Tuesday, April 12, 2022
Session Time: 9:00 AM – 12:30 PM
Presenter: Stephanie Jungmichel
About CDR-Life Inc.
CDR-Life is a privately-held, biotherapeutics company leveraging its unique antibody technology, M-gager(R), to target highly cancer-specific intracellular proteins presented on the major histocompatibility complex (MHC.) CDR-Life is advancing a robust pipeline of novel fully cancer-directed T cell engagers in various solid tumors. The team behind CDR-Life has extensive experience in all key areas of biological development and hold numerous patents and had previously invented new marketed medicines. CDR-Life has a strategic partnership with Boehringer Ingelheim to develop an antibody fragment-based therapeutic for geographic atrophy, a leading cause of blindness worldwide. For more information, please visit cdr-life.com and follow the Company on Twitter and LinkedIn.
Bjorn Peters, CBO
Phone: +41 44 515 98 98